Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana, Vrazov trg 2, 1000 Ljubljana, Slovenia.
Centre for Fabry Disease, General Hospital Slovenj Gradec, Gosposvetska cesta 1, 2380 Slovenj Gradec, Slovenia.
Genes (Basel). 2021 Jul 9;12(7):1057. doi: 10.3390/genes12071057.
Current biomarkers of Fabry nephropathy lack sensitivity in detecting early kidney damage and do not predict progression of nephropathy. Urinary extracellular vesicles (uEVs) and their molecular cargo could reflect early changes in renal impairment as they are secreted by the cells lining the urinary tract. We aimed to conduct a proof-of-concept study to investigate whether analysis of uEV characteristics and expression of uEV-derived microRNAs (miRNAs) could be applicable in studies to predict the development and progression of nephropathy in Fabry disease. A total of 20 Fabry patients were divided into two groups, depending on the presence of nephropathy. Chronological urine samples collected during 10-year follow-up were used for uEVs isolation with size exclusion chromatography. Nanoparticle tracking analysis was used to determine concentration and size of uEVs. We evaluated the expression of five uEV-derived miRNAs by qPCR (miR-23a-3p, miR-29a-3p, miR-30b-5p, miR-34a-5p, miR-200a-3p). There was no difference in the concentration and size of uEVs between patients with and without nephropathy at last follow-up or longitudinally. However, we found increased expression of miR-29a-3p and miR-200a-3p in uEVs isolated from chronological samples of patients with Fabry nephropathy. This may indicate an attempt by the organism to prevent the progression of renal damage leading to end-stage renal disease as previously reported in type 1 diabetes. In addition, we found an increased expression of miR-30b-5p in the 10-year period in uEVs of patients without renal dysfunction. miR-30b-5 was reported to have a protective role in podocyte injury and may possibly be important in Fabry nephropathy. These findings indicate that uEVs and their molecular cargo could be a promising target of studies focusing on elucidation of Fabry nephropathy. Nevertheless, total concentration and size of uEVs were neither indicative of the presence nor progression of Fabry nephropathy, while the role of the analyzed miRNAs in Fabry nephropathy progression was merely indicated and needs further in-depth studies.
目前用于检测早期肾损伤的法布里肾病生物标志物缺乏敏感性,也无法预测肾病的进展。尿细胞外囊泡(uEVs)及其分子物质可以反映肾脏损伤的早期变化,因为它们是由泌尿道衬里细胞分泌的。我们旨在进行一项概念验证研究,以调查分析 uEV 特征和 uEV 衍生 microRNAs(miRNAs)的表达是否可用于预测法布里病肾病的发生和进展。总共 20 名法布里病患者根据是否存在肾病分为两组。在 10 年的随访期间收集了尿液样本,通过分子筛层析法分离 uEVs。通过纳米颗粒跟踪分析确定 uEVs 的浓度和大小。我们通过 qPCR 评估了 5 种 uEV 衍生 miRNA 的表达(miR-23a-3p、miR-29a-3p、miR-30b-5p、miR-34a-5p、miR-200a-3p)。在最后一次随访或纵向随访时,没有发现无肾病患者和有肾病患者的 uEV 浓度和大小存在差异。然而,我们发现法布里肾病患者的 uEV 中 miR-29a-3p 和 miR-200a-3p 的表达增加。这可能表明机体试图阻止导致终末期肾病的肾脏损伤进展,这与之前在 1 型糖尿病中报道的情况类似。此外,我们还发现 uEVs 中的 miR-30b-5p 在 10 年内的表达增加,而这些患者没有肾功能障碍。miR-30b-5 被报道在足细胞损伤中具有保护作用,在法布里肾病中可能很重要。这些发现表明,uEVs 及其分子物质可能是阐明法布里肾病的研究的一个有前途的靶点。然而,uEVs 的总浓度和大小既不能提示法布里肾病的存在,也不能提示其进展,而分析的 miRNAs 在法布里肾病进展中的作用仅被提示,需要进一步深入研究。